JP2018522881A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522881A5
JP2018522881A5 JP2017568264A JP2017568264A JP2018522881A5 JP 2018522881 A5 JP2018522881 A5 JP 2018522881A5 JP 2017568264 A JP2017568264 A JP 2017568264A JP 2017568264 A JP2017568264 A JP 2017568264A JP 2018522881 A5 JP2018522881 A5 JP 2018522881A5
Authority
JP
Japan
Prior art keywords
dose
administered
antibody
pharmaceutical composition
multiple myeloma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017568264A
Other languages
English (en)
Japanese (ja)
Other versions
JP6754785B2 (ja
JP2018522881A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/039723 external-priority patent/WO2017003990A1/en
Publication of JP2018522881A publication Critical patent/JP2018522881A/ja
Publication of JP2018522881A5 publication Critical patent/JP2018522881A5/ja
Application granted granted Critical
Publication of JP6754785B2 publication Critical patent/JP6754785B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017568264A 2015-06-29 2016-06-28 免疫治療投与レジメンおよびその組合せ Active JP6754785B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562185968P 2015-06-29 2015-06-29
US62/185,968 2015-06-29
US201562239965P 2015-10-11 2015-10-11
US62/239,965 2015-10-11
US201562262574P 2015-12-03 2015-12-03
US62/262,574 2015-12-03
PCT/US2016/039723 WO2017003990A1 (en) 2015-06-29 2016-06-28 Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer

Publications (3)

Publication Number Publication Date
JP2018522881A JP2018522881A (ja) 2018-08-16
JP2018522881A5 true JP2018522881A5 (enExample) 2019-07-25
JP6754785B2 JP6754785B2 (ja) 2020-09-16

Family

ID=56409706

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017568264A Active JP6754785B2 (ja) 2015-06-29 2016-06-28 免疫治療投与レジメンおよびその組合せ

Country Status (20)

Country Link
US (2) US10925867B2 (enExample)
EP (2) EP3950065A1 (enExample)
JP (1) JP6754785B2 (enExample)
CN (1) CN107949425A (enExample)
BR (1) BR112017027692A2 (enExample)
CA (1) CA2990478A1 (enExample)
CY (1) CY1124543T1 (enExample)
DK (1) DK3313528T3 (enExample)
EA (1) EA035888B1 (enExample)
ES (1) ES2886657T3 (enExample)
HR (1) HRP20211478T1 (enExample)
HU (1) HUE056491T2 (enExample)
LT (1) LT3313528T (enExample)
MX (1) MX391581B (enExample)
PL (1) PL3313528T3 (enExample)
PT (1) PT3313528T (enExample)
RS (1) RS62352B1 (enExample)
SI (1) SI3313528T1 (enExample)
SM (1) SMT202100567T1 (enExample)
WO (1) WO2017003990A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202300081T1 (it) * 2014-08-22 2023-05-12 Celgene Corp Metodi di trattamento di mieloma multiplo con composti immunomodulatori in combinazione con anticorpi
PL3313528T3 (pl) * 2015-06-29 2021-12-13 Bristol-Myers Squibb Company Schematy dawkowania immunoterapeutycznego obejmujące pomalidomid i przeciwciało anty-cs1 w leczeniu raka
EP3488851A1 (en) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA204125A (en) 1920-09-21 Sylvester Pratt Edwin Gramophone operated toy
US819826A (en) 1905-12-14 1906-05-08 Frank R Welcher Stanchion.
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
DK2112166T3 (en) 1998-12-23 2019-02-04 Pfizer Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
SK287200B6 (sk) 1999-02-22 2010-03-08 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) C-21 modifikované epotilóny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a použitie
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
US7041499B2 (en) 2001-12-12 2006-05-09 University Of North Texas Health Science Center Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
CN1981761B (zh) * 2002-05-17 2011-10-12 细胞基因公司 使用免疫调节性化合物用于制备治疗和控制癌症和其它疾病药物中的应用及组合物
PL216630B1 (pl) 2002-10-17 2014-04-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US6958115B2 (en) 2003-06-24 2005-10-25 The United States Of America As Represented By The Secretary Of The Navy Low temperature refining and formation of refractory metals
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
PT2068874E (pt) * 2006-08-07 2015-05-21 Abbvie Biotherapeutics Inc Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-csi
EP2069478A2 (en) 2006-08-07 2009-06-17 PDL BioPharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
CN101534860B (zh) * 2006-08-07 2013-03-27 艾伯特生物治疗学公司 使用抗cs1-抗体治疗多发性骨髓瘤的组合物和方法
JP2010500370A (ja) * 2006-08-07 2010-01-07 ピーディーエル バイオファーマ，インコーポレイティド 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法
KR20110096536A (ko) 2008-10-31 2011-08-30 애보트 바이오테라퓨틱스 코포레이션 희귀 림프종의 치료를 위한 항ｃｓ1 항체의 용도
EP3199149A1 (en) 2009-05-19 2017-08-02 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
WO2011053321A1 (en) 2009-10-30 2011-05-05 University Of Arkansas For Medical Science Use of autologous effector cells for treatment of multiple myeloma
WO2011053322A1 (en) 2009-10-30 2011-05-05 University Of Arkansas For Medical Science Use of autologous effector cells and antibodies for treatment of multiple myeloma
US9506481B1 (en) 2013-01-31 2016-11-29 Daniel Theobald High force hydraulic actuator
HK1232121A1 (zh) * 2014-01-13 2018-01-05 University Of Central Florida Research Foundation, Inc. 作为抗氧化治疗的富勒烯化合物
SMT202300081T1 (it) 2014-08-22 2023-05-12 Celgene Corp Metodi di trattamento di mieloma multiplo con composti immunomodulatori in combinazione con anticorpi
JP2017537893A (ja) * 2014-10-31 2017-12-21 アッヴィ・バイオセラピューティクス・インコーポレイテッド 抗ｃｓ１抗体および抗体薬結合体
PL3313528T3 (pl) * 2015-06-29 2021-12-13 Bristol-Myers Squibb Company Schematy dawkowania immunoterapeutycznego obejmujące pomalidomid i przeciwciało anty-cs1 w leczeniu raka

Similar Documents

Publication Publication Date Title
JP2013501731A5 (enExample)
JP2014533279A5 (enExample)
JP2016530280A5 (enExample)
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
JP2020516646A5 (enExample)
JP2019517549A5 (enExample)
JP2016518387A5 (enExample)
JP2012102122A5 (enExample)
RU2017132877A (ru) Комбинация антагониста pd-1 и эрибулина для лечения рака
JP2018508516A5 (enExample)
JP2015505564A5 (enExample)
RU2016151757A (ru) Антагонисты pdl-1 и pd-1 для лечения hpv-отрицательных форм рака
JP2014500278A5 (enExample)
JP2015500822A5 (enExample)
JP2018090566A5 (enExample)
JP2017537927A5 (enExample)
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
JP2018522881A5 (enExample)
JOP20190019A1 (ar) تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
JP2016505050A5 (enExample)
RU2017126212A (ru) Композиция
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
HRP20211478T1 (hr) Imunoterapijski režimi doziranja koji obuhvaćaju pomalidomid i anti-cs1 antitijelo za liječenje raka
WO2012134915A1 (en) Ezatiostat for treating multiple myeloma